Search

Displaying results 2511 - 2520 of 3599 in total
  1. Drug

    KOS-1584

    go.drugbank.com/drugs/DB05903
    Investigational

    KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased pote...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  2. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  3. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was f...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Acetylcysteine

    go.drugbank.com/drugs/DB06151
    ApprovedInvestigational

    Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...

  5. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also be...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

    Categories: P-glycoprotein inhibitors
  8. Drug

    Udenafil

    go.drugbank.com/drugs/DB06267
    Approved

    Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  10. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors.

    Categories: P-glycoprotein substrates, Dopamine D2 Receptor Antagonists